Drug intelligence / Profile preview

APH03867

Development stage: Unknown
Lead developer: Apichope Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

APH03867 is an oral, non-peptide small-molecule inhibitor of urate transporter 1 (URAT1) developed by Guangzhou Yipinred Pharmaceutical (a subsidiary of ApicHope). It is designed for the treatment of gout accompanied by hyperuricemia. By selectively inhibiting URAT1 in the proximal renal tubules, APH03867 blocks the reabsorption of uric acid, thereby promoting its excretion in urine and lowering serum uric acid levels. In August 2026, the National Medical Products Administration (NMPA) of China approved its clinical trial application, and it is currently in Phase I clinical development in China.

Other names: APH03867 tabletsAPH-03867 tabletsAPH 03867 tabletsAPH03867片

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on APH03867.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APH03867.

Explore the full profile